Insulin resistance postburn: Underlying mechanisms and current therapeutic strategies

Journal of Burn Care and Research

Volumn 29, Issue 5, 2008, Pages 683-694

  Gauglitz, Gerd G ^a,b   Herndon, David N ^a,b   Jeschke, Marc G ^a,b  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BIGUANIDE; FENOFIBRATE; GLUCOSE TRANSPORTER 4; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; METFORMIN; OXANDROLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOMATOMEDIN C; SUPEROXIDE; TESTOSTERONE;

BURN; BURN PATIENT; CRITICALLY ILL PATIENT; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERMETABOLISM; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; MORBIDITY; MORTALITY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRESS;

ANTILIPEMIC AGENTS; BLOOD GLUCOSE; BURNS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; PPAR GAMMA; PROCETOFEN; RISK FACTORS; TIME FACTORS;

EID: 55249116335     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e31818481ce     Document Type: Review

References (154)

1. American Burn Association/American College of Surgeons. Guidelines for the operation of burn centers. J Burn Care Res 2007;28:134-41.
2. Nguyen TT, Gilpin DA, Meyer NA, Herndon DN. Current treatment of severely burned patients. Ann Surg 1996;223:14-25.
3. Brigham PA, McLoughlin E. Burn incidence and medical care use in the United States: estimates, trends, and data sources. J Burn Care Rehabil 1996;17:95-107.
4. Wolf SE. Critical care in the severely burned: organ support and management of complications. In: Herndon DN, editor. Total burn care. 3rd ed. London: Saunders Elsevier; 2007. p. 454-76.
5. Herndon DN. Total burn care. 3rd ed. Philadelphia: Saunders Elsevier; 2007.
6. Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004;363:1895-902.
7. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001;17:107-24.
8. Bernard C. Leçons sur les phénomènes de la vie communs aux animaux et aux végétaux. Vol. 1. Paris, France: J.B. Baillière et Fils; 1878.
9. Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. Arch Neurol 2001;58:1209-12.
10. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001;15:533-51.
11. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
12. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-8.
13. Pidcoke HF, Wade CE, Wolf SE. Insulin and the burned patient. Crit Care Med 2007;35:S524-30.
14. McMurry JF Jr. Wound healing with diabetes mellitus. Better glucose control for better wound healing in diabetes. Surg Clin North Am 1984;64:769-78.
15. Mowlavi A, Andrews K, Milner S, Herndon DN, Heggers JP. The effects of hyperglycemia on skin graft survival in the burn patient. Ann Plast Surg 2000;45:629-32.
16. Gore DC, Chinkes DL, Hart DW, Wolf SE, Herndon DN, Sanford AP. Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients. Crit Care Med 2002;30:2438-42.
17. Guvener M, Pasaoglu I, Demircin M, Oc M. Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting. Endocr J 2002;49:531-7.
18. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, Desai M. Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 2001;51:540-4.
19. Thorell A, Efendic S, Gutniak M, Haggmark T, Ljungqvist O. Development of postoperative insulin resistance is associated with the magnitude of operation. Eur J Surg 1993;159:593-9.
20. Garcia-Avello A, Lorente JA, Cesar-Perez J, et al. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb Res 1998;89:59-64.
21. Christiansen C, Toft P, Jorgensen HS, et al. Hyperglycaemia and mortality in critically ill patients. A prospective study. Intensive Care Med 2004;30:1685-8.
22. Ingels C, Debaveye Y, Milants I, et al. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 2006;27:2716-24.
23. Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000;128:312-9.
24. Reiss E, Pearson E, Artz CP. The metabolic response to burns. J Clin Invest 1956;35:62-77.
25. Yu YM, Tompkins RG, Ryan CM, Young VR. The metabolic basis of the increase in energy expenditure in severely burned patients. JPEN J Parenter Enteral Nutr 1999;23:160-8.
26. Mlcak RP, Jeschke MG, Barrow RE, Herndon DN. The influence of age and gender on resting energy expenditure in severely burned children. Ann Surg 2006;244:121-30.
27. Przkora R, Barrow RE, Jeschke MG, et al. Body composition changes with time in pediatric burn patients. J Trauma 2006;60:968-71.
28. Dolecek R. Endocrine changes after burn trauma - a review. Keio J Med 1989;38:262-76.
29. Jeffries MK, Vance ML. Growth hormone and cortisol secretion in patients with burn injury. J Burn Care Rehabil 1992;13:391-5.
30. Klein GL, Bi LX, Sherrard DJ, et al. Evidence supporting a role of glucocorticoids in short-term bone loss in burned children. Osteoporos Int 2004;15:468-74.
31. Goodall M, Stone C, Haynes BW Jr. Urinary output of adrenaline and noradrenaline in severe thermal burns. Ann Surg 1957;145:479-87.
32. Coombes EJ, Batstone GF. Urine cortisol levels after burn injury. Burns Incl Therm Inj 1982;8:333-7.
33. Norbury WB, Herndon, DN. Modulation of the hypermetabolic response after burn injury. In: Herndon DN, editor. Total burn care. 3rd ed. New York: Saunders Elsevier; 2007. p. 420-33.
34. Sheridan RL. A great constitutional disturbance. N Engl J Med 2001;345:1271-2.
35. Pereira C, Murphy K, Jeschke M, Herndon DN. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol 2005;37:1948-61.
36. Wolfe RR. Review: acute versus chronic response to burn injury. Circ Shock 1981;8:105-15.
37. Cuthbertson DP, Angeles Valero Zanuy MA, Leon Sanz ML. Post-shock metabolic response. 1942. Nutr Hosp 2001;16:175-82.
38. Galster AD, Bier DM, Cryer PE, Monafo WW. Plasma palmitate turnover in subjects with thermal injury. J Trauma 1984;24:938-45.
39. Cree MG, Aarsland A, Herndon DN, Wolfe RR. Role of fat metabolism in burn trauma-induced skeletal muscle insulin resistance. Crit Care Med 2007;35:S476-83.
40. Childs C, Heath DF, Little RA, Brotherston M. Glucose metabolism in children during the first day after burn injury. Arch Emerg Med 1990;7:135-47.
41. Jeschke MG, Mlcak RP, Finnerty CC, et al. Burn size determines the inflammatory and hypermetabolic response. Crit Care 2007;11:R90.
42. Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. AACN Clin Issues 2006;17:50-5.
43. Robinson LE, van Soeren MH. Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control. AACN Clin Issues 2004;15:45-62.
44. Khani S, Tayek JA. Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. Clin Sci (Lond) 2001;101:739-47.
45. Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987;317:403-8.
46. Gore DC, Jahoor F, Wolfe RR, Herndon DN. Acute response of human muscle protein to catabolic hormones. Ann Surg 1993;218:679-84.
47. Carlson GL. Insulin resistance and glucose-induced thermogenesis in critical illness. Proc Nutr Soc 2001;60:381-8.
48. Wolfe RR, Durkot MJ, Allsop JR, Burke JF. Glucose metabolism in severely burned patients. Metabolism 1979;28:1031-9.
49. Cree MG, Zwetsloot JJ, Herndon DN, et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 2007;245:214-21.
50. Hunt DG, Ivy JL. Epinephrine inhibits insulin-stimulated muscle glucose transport. J Appl Physiol 2002;93:1638-43.
51. Gustavson SM, Chu CA, Nishizawa M, et al. Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog. Am J Physiol Endocrinol Metab 2003;284:E695-707.
52. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690-4.
53. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.
54. Akita S, Akino K, Ren SG, Melmed S, Imaizumi T, Hirano A. Elevated circulating leukemia inhibitory factor in patients with extensive burns. J Burn Care Res 2006;27:221-5.
55. Fan J, Li YH, Wojnar MM, Lang CH. Endotoxin-induced alterations in insulin-stimulated phosphorylation of insulin receptor, IRS-1, and MAP kinase in skeletal muscle. Shock 1996;6:164-70.
56. del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol 1999;276:E849-55.
57. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006;147:2458-67.
58. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 1983;308:553-8.
59. Jahoor F, Desai M, Herndon DN, Wolfe RR. Dynamics of the protein metabolic response to burn injury. Metabolism 1988;37:330-7.
60. Saffle JR, Graves C. Nutritional support of the burned patient. In: Herndon DN, editor. Total burn care. 3rd ed. London: Saunders Elsevier; 2007. p. 398-419.
61. Hart DW, Wolf SE, Chinkes DL, et al. Determinants of skeletal muscle catabolism after severe burn. Ann Surg 2000;232:455-65.
62. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981;30:1000-7.
63. Flakoll PJ, Hill JO, Abumrad NN. Acute hyperglycemia enhances proteolysis in normal man. Am J Physiol 1993;265:E715-21.
64. McClave SA, Snider HL. Use of indirect calorimetry in clinical nutrition. Nutr Clin Pract 1992;7:207-21.
65. Arora NS, Rochester DF. Respiratory muscle strength and maximal voluntary ventilation in undernourished patients. Am Rev Respir Dis 1982;126:5-8.
66. Rutan RL, Herndon DN. Growth delay in postburn pediatric patients. Arch Surg 1990;125:392-5.
67. Atiyeh BS, Dham R, Kadry M, et al. Benefit-cost analysis of moist exposed burn ointment. Burns 2002;28:659-63.
68. Lofts JA. Cost analysis of a major burn. N Z Med J 1991;104:488-90.
69. Munster AM, Smith-Meek M, Sharkey P. The effect of early surgical intervention on mortality and cost-effectiveness in burn care, 1978-91. Burns 1994;20:61-4.
70. Ramzy PI, Barret JP, Herndon DN. Thermal injury. Crit Care Clin 1999;15:333-52, ix.
71. Chan BP, Kochevar IE, Redmond RW. Enhancement of porcine skin graft adherence using a light-activated process. J Surg Res 2002;108:77-84.
72. Gore DC, Honeycutt D, Jahoor F, Wolfe RR, Herndon DN. Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients. Arch Surg 1991;126:38-43.
73. Debroy MA, Wolf SE, Zhang XJ, et al. Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J Trauma 1999;47:904-11.
74. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001;233:556-64.
75. Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN, Wolfe RR. Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med 2001;29:1936-42.
76. Herndon DN, Han DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001;345:1223-9.
77. Pereira CT, Murphy KD, Herndon DN. Altering metabolism. J Burn Care Rehabil 2005;26:194-9.
78. Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp 2007;280:238-51.
79. Sakurai Y, Aarsland A, Herndon DN, et al. Stimulation of muscle protein synthesis by long-term insulin infusion in severely burned patients. Ann Surg 1995;222:283-94; 294-7.
80. Ferrando AA, Chinkes DL, Wolf SE, Matin S, Herndon DN, Wolfe RR. A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns. Ann Surg 1999;229:11-8.
81. Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg 1990;212:424-31.
82. Moller S, Jensen M, Svensson P, Skakkebaek NE. Insulin-like growth factor 1 (IGF-1) in burn patients. Burns 1991;17:279-81.
83. Herndon DN, Ramzy PI, DebRoy MA, et al. Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg 1999;229:713-22.
84. Demling RH, DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 1997;43:47-51.
85. Wolf SE, Thomas SJ, Dasu MR, et al. Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg 2003;237:801-11.
86. Singh KP, Prasad R, Chari PS, Dash RJ. Effect of growth hormone therapy in burn patients on conservative treatment. Burns 1998;24:733-8.
87. Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil 1997;18:223-7.
88. Gore DC, Honeycutt D, Jahoor F, Barrow RE, Wolfe R, Herndon DN. Propranolol diminishes extremity blood flow in burned patients. Ann Surg 1991;213:568-74.
89. Pierre EJ, Barrow RE, Hawkins HK, et al. Effects of insulin on wound healing. J Trauma 1998;44:342-5.
90. Thomas SJ, Morimoto K, Herndon DN, et al. The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. Surgery 2002;132:341-7.
91. Zhang XJ, Chinkes DL, Wolf SE, Wolfe RR. Insulin but not growth hormone stimulates protein anabolism in skin would and muscle. Am J Physiol 1999;276:E712-20.
92. Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004;145:4084-93.
93. Jeschke MG, Klein D, Herndon DN. Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 2004;239:553-60.
94. Jeschke MG, Rensing H, Klein D, et al. Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J Hepatol 2005;42:870-9.
95. Klein D, Schubert T, Horch RE, Jauch KW, Jeschke MG. Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma. Ann Surg 2004;240:340-9.
96. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 2000;85:2572-5.
97. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 2000;49:147-50.
98. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an antiinflammatory effect? J Clin Endocrinol Metab 2001;86:3257-65.
99. Pham TN, Warren AJ, Phan HH, Molitor F, Greenhalgh DG, Palmieri TL. Impact of tight glycemic control in severely burned children. J Trauma 2005;59:1148-54.
100. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003;88:1082-8.
101. Dandona P, Chaudhuri A, Mohanty P, Ghanim H. Antiinflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 2007;10:511-7.
102. van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
103. Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 2006;55:1096-105.
104. van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003;31:359-66.
105. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
106. Langouche L, Vanhorebeek I, van den Berghe G. Therapy insight: the effect of tight glycemic control in acute illness. Nat Clin Pract Endocrinol Metab 2007;3:270-8.
107. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003;290:2041-7.
108. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
109. Gore DC, Wolf SE, Herndon DN, Wolfe RR. Metformin blunts stress-induced hyperglycemia after thermal injury. J Trauma 2003;54:555-61.
110. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med 1995;333:541-9.
111. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
112. Gore DC, Herndon DN, Wolfe RR. Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma 2005;59:316-23.
113. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
114. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978;14:75-87.
115. Riesenman PJ, Braithwaite SS, Cairns BA. Metformin-associated lactic acidosis in a burn patient. J Burn Care Res 2007;28:342-7.
116. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-63.
117. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995;18:779-84.
118. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594-602.
119. White MF. The insulin signalling system and the IRS proteins. Diabetologia 1997;40 (Suppl 2):S2-17.
120. Kahn CR, White MF, Shoelson SE, et al. The insulin receptor and its substrate: molecular determinants of early events in insulin action. Recent Prog Horm Res 1993;48:291-339.
121. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001;24:588-97.
122. Ruderman NB, Kapeller R, White MF, Cantley LC. Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci USA 1990;87:1411-5.
123. Folli F, Saad MJ, Backer JM, Kahn CR. Insulin stimulation of phosphatidylinositol 3-kinase activity and association with insulin receptor substrate 1 in liver and muscle of the intact rat. J Biol Chem 1992;267:22171-7.
124. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994;94:1543-9.
125. Saltiel AR, Pessin JE. Insulin signaling in microdomains of the plasma membrane. Traffic 2003;4:711-6.
126. Yu XX, Pandey SK, Booten SL, Murray SF, Monia BP, Bhanot S. Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression. Am J Physiol Endocrinol Metab 2008;294:E530-9.
127. Ikezu T, Okamoto T, Yonezawa K, Tompkins RG, Martyn JA. Analysis of thermal injury-induced insulin resistance in rodents. Implication of postreceptor mechanisms. J Biol Chem 1997;272:25289-95.
128. Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med 2004;10:65-71.
129. Thurmond DC, Pessin JE. Molecular machinery involved in the insulin-regulated fusion of GLUT4-containing vesicles with the plasma membrane (review). Mol Membr Biol 2001;18:237-45.
130. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96.
131. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000;275:9047-54.
132. Gao Z, Hwang D, Bataille F, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 2002;277:48115-21.
133. Gauglitz GG, Song J, Herndon DN, et al. Characterization of the inflammatory response during acute and postacute phases after severe burn. Shock 2008; [epub ahead of print].
134. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-9.
135. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61.
136. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29.
137. Hampton RY. ER stress response: getting the UPR hand on misfolded proteins. Curr Biol 2000;10:R518-21.
138. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000;101:451-4.
139. Urano F, Wang X, Bertolotti A, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000;287:664-6.
140. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98:13681-6.
141. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6.
142. Ricci R, Sumara G, Sumara I, et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004;306:1558-61.
143. Kaneto H, Nakarani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004;10:1128-32.
144. Liu G, Rondinone CM. JNK: bridging the insulin signaling and inflammatory pathway. Curr Opin Investig Drugs 2005;6:979-87.
145. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006;313:1137-40.
146. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-801.
147. Sugita H, Fujimoto M, Yasukawa T, et al. Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 2005;280:14203-11.
148. Xie QW, Cho HJ, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992;256:225-8.
149. Kaneki M, Shimizu N, Yamada D, Chang K. Nitrosative stress and pathogenesis of insulin resistance. Antioxid Redox Signal 2007;9:319-29.
150. Krishnegowda G, Hajjar AM, Zhu J, et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 2005;280:8606-16.
151. Pawate S, Bhat NR. C-Jun N-terminal kinase (JNK) regulation of iNOS expression in glial cells: predominant role of JNK1 isoform. Antioxid Redox Signal 2006;8:903-9.
152. Perrcault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001;7:1138-43.
153. Carvalho-Filho MA, Ueno M, Hirabara SM, et al. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 2005;54:959-67.
154. Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-acrivated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 2004;279:20767-74.